{"title":"微血浆非手术治疗皮肤松弛症。","authors":"Jeffrey T S Hsu","doi":"10.36849/JDD.8635","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong> Dermatochalasis is characterized by the presence of redundant and loose upper eyelid skin, which occurs as part of the aging process and is often considered aesthetically undesirable. Currently, the gold standard for treatment is surgical blepharoplasty; however, non-surgical solutions are frequently requested. This study investigates the safety and efficacy of microplasma as a non-surgical method for treating dermatochalasis.</p><p><strong>Methods: </strong> Pre-clinic investigations were performed in vivo on porcine skin. Three pigs were treated with an increasing energy exposure of microplasma and biopsy samples were analyzed via histology. Subsequently, in a prospective clinical trial, 13 subjects with dermatochalasis were treated with MicroPlasma applicator. The subjects received 1 to 2 treatments with a treatment interval of 4 to 16 weeks. Results were assessed by blinded evaluation of pre- and post-treatment pictures and a patient questionnaire.</p><p><strong>Results: </strong> The in vivo porcine study showed skin ablation and dermal coagulation consistent with increasing plasma energy delivery, and subsequent healing process as expected, with neovascularization and fibroblast proliferation. In the clinical patient trial, blinded evaluations revealed improvement in the Dermatochalasis Scale (P<0.01) and improvement in the Global Aesthetics Improvement Scale. There were no serious adverse events.</p><p><strong>Conclusion: </strong> Microplasma is a successful non-surgical treatment option to reduce redundant skin of the upper eyelid with minimal adverse effects. J Drugs Dermatol. 2025;24(2):134-141. doi:10.36849/JDD.8635.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 2","pages":"134-141"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Non-Surgical Correction of Dermatochalasis Using Microplasma.\",\"authors\":\"Jeffrey T S Hsu\",\"doi\":\"10.36849/JDD.8635\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong> Dermatochalasis is characterized by the presence of redundant and loose upper eyelid skin, which occurs as part of the aging process and is often considered aesthetically undesirable. Currently, the gold standard for treatment is surgical blepharoplasty; however, non-surgical solutions are frequently requested. This study investigates the safety and efficacy of microplasma as a non-surgical method for treating dermatochalasis.</p><p><strong>Methods: </strong> Pre-clinic investigations were performed in vivo on porcine skin. Three pigs were treated with an increasing energy exposure of microplasma and biopsy samples were analyzed via histology. Subsequently, in a prospective clinical trial, 13 subjects with dermatochalasis were treated with MicroPlasma applicator. The subjects received 1 to 2 treatments with a treatment interval of 4 to 16 weeks. Results were assessed by blinded evaluation of pre- and post-treatment pictures and a patient questionnaire.</p><p><strong>Results: </strong> The in vivo porcine study showed skin ablation and dermal coagulation consistent with increasing plasma energy delivery, and subsequent healing process as expected, with neovascularization and fibroblast proliferation. In the clinical patient trial, blinded evaluations revealed improvement in the Dermatochalasis Scale (P<0.01) and improvement in the Global Aesthetics Improvement Scale. There were no serious adverse events.</p><p><strong>Conclusion: </strong> Microplasma is a successful non-surgical treatment option to reduce redundant skin of the upper eyelid with minimal adverse effects. J Drugs Dermatol. 2025;24(2):134-141. doi:10.36849/JDD.8635.</p>\",\"PeriodicalId\":15566,\"journal\":{\"name\":\"Journal of Drugs in Dermatology\",\"volume\":\"24 2\",\"pages\":\"134-141\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drugs in Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.36849/JDD.8635\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8635","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Non-Surgical Correction of Dermatochalasis Using Microplasma.
Background: Dermatochalasis is characterized by the presence of redundant and loose upper eyelid skin, which occurs as part of the aging process and is often considered aesthetically undesirable. Currently, the gold standard for treatment is surgical blepharoplasty; however, non-surgical solutions are frequently requested. This study investigates the safety and efficacy of microplasma as a non-surgical method for treating dermatochalasis.
Methods: Pre-clinic investigations were performed in vivo on porcine skin. Three pigs were treated with an increasing energy exposure of microplasma and biopsy samples were analyzed via histology. Subsequently, in a prospective clinical trial, 13 subjects with dermatochalasis were treated with MicroPlasma applicator. The subjects received 1 to 2 treatments with a treatment interval of 4 to 16 weeks. Results were assessed by blinded evaluation of pre- and post-treatment pictures and a patient questionnaire.
Results: The in vivo porcine study showed skin ablation and dermal coagulation consistent with increasing plasma energy delivery, and subsequent healing process as expected, with neovascularization and fibroblast proliferation. In the clinical patient trial, blinded evaluations revealed improvement in the Dermatochalasis Scale (P<0.01) and improvement in the Global Aesthetics Improvement Scale. There were no serious adverse events.
Conclusion: Microplasma is a successful non-surgical treatment option to reduce redundant skin of the upper eyelid with minimal adverse effects. J Drugs Dermatol. 2025;24(2):134-141. doi:10.36849/JDD.8635.
期刊介绍:
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.